Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status Prescription; Discontinued
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood cholesterol abnormal13.12.01.009--Not Available
Blood cholesterol increased13.12.01.002--
Blood creatine increased13.13.01.0010.000799%Not Available
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine abnormal13.13.01.0020.000533%Not Available
Blood creatinine increased13.13.01.0040.010124%
Blood glucose decreased13.02.02.0010.000799%Not Available
Blood glucose increased13.02.02.002--Not Available
Blood lactate dehydrogenase abnormal13.04.02.0070.000533%Not Available
Blood lactate dehydrogenase increased13.04.02.0020.002398%
Blood magnesium decreased13.11.01.008--Not Available
Blood potassium decreased13.11.01.010--Not Available
Blood potassium increased13.11.01.0110.000799%Not Available
Blood pressure abnormal13.14.03.0010.002131%Not Available
Blood pressure decreased13.14.03.002--Not Available
Blood pressure increased13.14.03.0050.032769%Not Available
Blood pressure systolic increased13.14.03.0060.001598%Not Available
Blood sodium decreased13.11.01.0120.001332%Not Available
Blood thyroid stimulating hormone increased13.10.03.0060.004263%
Blood triglycerides increased13.12.03.001--Not Available
Blood urea increased13.13.01.0060.001598%Not Available
Body temperature increased13.15.01.001--Not Available
Bone neoplasm16.29.01.001; 15.09.02.0010.000139%Not Available
Bone pain15.02.01.0010.003197%
Bradycardia02.03.02.002--Not Available
Brain herniation17.11.01.002; 12.01.10.0010.000139%Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchopulmonary aspergillosis11.03.01.002; 22.07.08.0010.000139%Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Burning sensation17.02.06.001; 08.01.09.0290.003463%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 28 Pages